Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Source: Eur Respir J 2004; 24 : 644-648 Year: 2004
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005
Combination versus monotherapy for nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 50-55 Year: 2007
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001
Safety and efficacy of CURB65 guided antibiotic therapy in community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010
Efficacy and safety of stepwise therapy in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 377s Year: 2006
Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB Source: Eur Respir J 2013; 41: 1386-1392 Year: 2013
Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis Source: Eur Respir J 2012; 39: 611-618 Year: 2012
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007
Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004
Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004
Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011
Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004
Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives Source: Eur Respir J 2004; 24: Suppl. 48, 185s Year: 2004
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Source: Eur Respir J 2012; 40: 1430-1442 Year: 2012